ImmunityBio Shares Climb 10% in June on Anktiva Immuno-Oncology Momentum
IBRX•Immuno-oncology and targeted therapies present expanded growth avenues as ImmunityBio’s Anktiva boosts natural killer, CD8+ T and memory T cells. The SPDR S&P Biotech ETF rose 17% in June while ImmunityBio shares advanced 10% during the month.
1. Sector Performance
The SPDR S&P Biotech ETF gained 17% in June, propelled by strong rallies in immuno-oncology stocks. ImmunityBio shares climbed 10% over the month while Sellas Life Sciences surged 53%, underscoring investor focus on cancer-treatment developers.
2. ImmunityBio's Role
ImmunityBio’s Anktiva is an approved immunotherapy that enhances natural killer, CD8+ T and memory T cells to strengthen anti-cancer immunity. This mechanism aligns with broader growth trends in immuno-oncology and targeted therapies.
3. M&A Outlook
Improved policy clarity, attractive valuations and looming patent expiries are expected to sustain biotech M&A activity. Market observers anticipate ImmunityBio could benefit from dealmaking as major drugmakers seek external assets to bolster pipelines.
